Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
Investor sentiment on the key benefit of its lead drug candidate could be impacted in the current quarter.
Viking Therapeutics (NASDAQ: VKTX) has secured $502 million in cash reserves as of now, with a significant milestone looming in 2026. The company is currently conducting two phase 3 trials for its flagship weight loss drug, VK2735, in both subcutaneous and oral formulations. Despite the trials being years away from yielding results, Viking Therapeutics claims to have sufficient funds to sustain operations until 2028.
What sets VK2735 apart in the competitive obesity market is its dual GLP-1 and GIP agonist properties. It has shown a more pronounced rate of weight loss compared to its competitors in earlier trials. Furthermore, VK2735 is being developed as a dual-formulation therapy, starting with an initial subcutaneous injection followed by a convenient oral maintenance dose. This combination of rapid weight loss and easy maintenance administration appears to be the key advantage for VK2735.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
